ARCH Venture Fund IX, L.P. is 10% at Vir Biotechnology, Inc. (VIR). They have made 1 open-market trade across 1 company since 2026, most recently 2026-07-01.
CIK 0001666306
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LYEL | 18,206,358 | $269.1M |
| BEAM | 3,521,519 | $90.9M |
| VIR | 207,590 | $2.3M |
| BOLD | 16,000 | $39K |
| Total | $362.3M |
Shares reported on the most recent Form 4, priced at the 2026-07-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BOLD | SELL | 2026-07-01 | 2026-07-06 | $2.49 | $40K | +0.2% | +12.7% | +5.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.